Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 juin 2026 08h35 HE | Source: Ambros Therapeutics, Inc.

Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management

IRVINE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc., today announced the appointment of Cris Calsada as Chief Financial Officer (CFO) and Claire Padgett, Ph.D., as Senior...
08 juin 2026 08h35 HE | Source: Ambros Therapeutics, Inc.

Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1

CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and...
31 mars 2026 08h35 HE | Source: Ambros Therapeutics, Inc.

Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new...